Artificial Cell Technologies
Artificial Cell Technologies (ACT) is a New Haven-based biotechnology company focused on redefining vaccine manufacturing through proprietary synthetic vaccine technology. Their innovative approach enables rapid, on-demand, and personalized vaccine production, significantly faster and more cost-effective than traditional methods. ACT's mission is to develop and deploy synthetic vaccines for infectious diseases, especially targeting the developing world, with a focus on decentralizing manufacturing and improving global health outcomes.
Industries
Nr. of Employees
small (1-50)
Artificial Cell Technologies
Products
Synthetic malaria vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting falciparum malaria, produced via multilayer polypeptide deposition onto particulate cores; reported progression toward Phase 1 clinical trial.
Synthetic RSV vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting respiratory syncytial virus (RSV) using multilayer polypeptide assembly onto particulate cores.
Synthetic malaria vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting falciparum malaria, produced via multilayer polypeptide deposition onto particulate cores; reported progression toward Phase 1 clinical trial.
Synthetic RSV vaccine candidate
Preclinical-stage synthetic microparticle vaccine candidate targeting respiratory syncytial virus (RSV) using multilayer polypeptide assembly onto particulate cores.
Services
Decentralized on-demand vaccine manufacturing
Mobile manufacturing service concept using compact aseptic cleanrooms and computer-controlled devices to produce synthetic vaccines near target populations.
Decentralized on-demand vaccine manufacturing
Mobile manufacturing service concept using compact aseptic cleanrooms and computer-controlled devices to produce synthetic vaccines near target populations.
Expertise Areas
- Synthetic vaccine manufacturing
- Layer-by-layer nanoparticle assembly
- Decentralized/mobile vaccine production
- Temperature-stable vaccine formulation
Key Technologies
- Electrostatic layer-by-layer deposition
- Polypeptide nanofilm multilayers
- Microparticle vaccine platforms
- Inorganic particulate cores (calcium carbonate) for particle scaffolds